Ligand Pharmaceuticals Incorporated Quick Ratio (LGND) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Ligand Pharmaceuticals Incorporated  (NASDAQ: LGND)

Ligand Pharmaceuticals Incorporated's Quick Ratio

LGND's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 0.75 below Ligand Pharmaceuticals Incorporated average.

Within Major Pharmaceutical Preparations industry 17 other companies have achieved higher Quick Ratio than Ligand Pharmaceuticals Incorporated in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 154 to 165.

Explain Quick Ratio?
How much Cash & cash equivalents LGND´s has?
What are LGND´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/LGND/financial-strength
https://api.csimarket.com/api/v1/companies/LGND/fundamentals
https://api.csimarket.com/api/v1/companies/LGND/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
LGND Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 1539.11 %
Y / Y Cash & cash equivalent Change -43.67 %
Quick Ratio MRQ 0.75
LGND's Total Ranking # 165
Seq. Current Liabilities Change 971.06 %
Seq. Cash & cash equivalent Change -70.7 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 18
Healthcare Sector # 30
Overall Market # 165


Quick Ratio Statistics
High Average Low
67.94 8.29 0.1
(Dec 31 2019)   (Sep 30 2013)




Financial Statements
Ligand Pharmaceuticals Incorporated's Current Liabilities $ 501 Millions Visit LGND's Balance sheet
Ligand Pharmaceuticals Incorporated's Cash & cash equivalent $ 374 Millions Visit LGND's Balance sheet
Source of LGND's Sales Visit LGND's Sales by Geography


Cumulative Ligand Pharmaceuticals Incorporated's Quick Ratio

LGND's Quick Ratio for the trailling 12 Months

LGND Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months 		(Mar 31 2026)
12 Months 		(Dec 31 2025)
12 Months 		(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 227.33 %
Y / Y Cash & cash equivalent TTM Growth 140.33 %
Quick Ratio TTM 5.86
Total Ranking TTM # 541
Seq. Current Liabilities TTM Growth 302.49 %
Seq. Cash & cash equivalent TTM Growth -7.33 %

Quick ratio ranking by company, industry and sector >> Back to LGND Financial Strength Comparisons >> Go to Compare LGND Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q3 2026 to $500.57 millions, cumulative Quick Ratio decreased to 5.86 above the LGND average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 431 other companies have achieved higher Quick Ratio than Ligand Pharmaceuticals Incorporated. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2306 to 3311.

Explain Quick Ratio?
How much Cash & cash equivalents LGND´s has?
What are LGND´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 432
Healthcare Sector # 881
Within the Market #


trailing twelve months Quick Ratio Statistics
High Average Low
9.24 1.69 0.11
(Jun 30 2026)   (Sep 30 2022)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Dianthus Therapeutics Inc   1.95 $ 55.686  Millions$ 28.515  Millions
Xeris Biopharma Holdings Inc   1.95 $ 262.164  Millions$ 134.479  Millions
Ars Pharmaceuticals Inc   1.95 $ 138.354  Millions$ 70.995  Millions
Lite Strategy Inc   1.92 $ 4.281  Millions$ 2.234  Millions
Mineralys Therapeutics Inc   1.91 $ 101.273  Millions$ 53.075  Millions
Amarin Corp Plcuk  1.85 $ 323.379  Millions$ 175.136  Millions
Mustang Bio inc   1.80 $ 14.276  Millions$ 7.947  Millions
Biovie Inc   1.78 $ 7.733  Millions$ 4.350  Millions
Alnylam Pharmaceuticals Inc   1.74 $ 3,587.255  Millions$ 2,063.006  Millions
Mallinckrodt Plc  1.74 $ 1,085.600  Millions$ 624.900  Millions
Insmed Inc  1.73 $ 1,146.626  Millions$ 662.181  Millions
Nkarta Inc   1.72 $ 48.354  Millions$ 28.072  Millions
Mannkind Corporation  1.67 $ 181.525  Millions$ 108.524  Millions
Verastem Inc   1.67 $ 172.801  Millions$ 103.328  Millions
Agios Pharmaceuticals Inc   1.66 $ 128.549  Millions$ 77.588  Millions
Bridgebio Pharma Inc   1.57 $ 1,538.855  Millions$ 977.237  Millions
Arcutis Biotherapeutics Inc   1.51 $ 259.460  Millions$ 172.357  Millions
Regeneron Pharmaceuticals Inc   1.50 $ 9,301.100  Millions$ 6,202.100  Millions
Emergent Biosolutions Inc   1.44 $ 175.700  Millions$ 122.000  Millions
Arbutus Biopharma Corp  1.39 $ 337.490  Millions$ 241.933  Millions
Compass Pathways Plc  1.36 $ 443.979  Millions$ 325.863  Millions
Sarepta Therapeutics Inc   1.34 $ 878.776  Millions$ 656.353  Millions
Zai Lab Limited  1.32 $ 559.658  Millions$ 424.249  Millions
Urogen Pharma Ltd   1.31 $ 96.901  Millions$ 74.031  Millions
Ani Pharmaceuticals Inc  1.28 $ 420.758  Millions$ 328.717  Millions
Vertex Pharmaceuticals Inc  1.26 $ 6,303.300  Millions$ 5,000.300  Millions
Nature s Sunshine Products inc   1.22 $ 89.377  Millions$ 73.488  Millions
Ovid Therapeutics Inc   1.16 $ 13.811  Millions$ 11.858  Millions
Filana Therapeutics Inc   1.12 $ 46.990  Millions$ 41.946  Millions
Phathom Pharmaceuticals Inc   1.06 $ 184.558  Millions$ 174.902  Millions

Date modified: 2026-10-31T17:28:39+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.